Pulmonary Stenosis

Pulmonary stenosis (PS) is a congenital cardiac outflow tract obstruction at the level of the pulmonary valve, the right ventricular outflow tract (RVOT), or the main pulmonary artery. It is one of the most common congenital heart defects in dogs and is also recognized in cats. The obstruction leads to right ventricular pressure overload, concentric hypertrophy, and progressive clinical signs ranging from asymptomatic murmurs to right-sided congestive heart failure and sudden death. The severity of stenosis is classified based on the peak systolic pressure gradient across the pulmonary valve, measured by Doppler echocardiography: mild (<50 mmHg), moderate (50-80 mmHg), and severe (>80 mmHg). Anatomically, PS can be valvular (most common), subvalvular (infundibular), or supravalvular, with valvular forms often associated with dysplastic valve leaflets. The condition may be isolated or accompanied by other congenital anomalies, such as ventricular septal defect or tetralogy of Fallot.

The exact etiology of pulmonary stenosis in dogs and cats is largely unknown, but a genetic basis is strongly suspected. In certain breeds, such as the English Bulldog, Boxer, and Beagle, a hereditary component has been documented, with an autosomal dominant or polygenic mode of inheritance proposed. In cats, PS is less common but may occur as a sporadic congenital defect. No specific infectious, toxic, or nutritional causes have been identified. The defect arises from abnormal development of the pulmonary valve and right ventricular outflow tract during embryogenesis, leading to varying degrees of leaflet thickening, fusion, or annular hypoplasia. In dysplastic valves, the leaflets are thickened and immobile, often with a hypoplastic annulus, whereas in typical valvular stenosis, the leaflets are fused into a dome-shaped diaphragm with a central orifice. Subvalvular stenosis results from a fibromuscular band or diffuse narrowing of the infundibulum, and supravalvular stenosis is rare, caused by a narrowing of the main pulmonary artery distal to the valve.

Pulmonary stenosis is one of the most common congenital heart defects in dogs, accounting for approximately 10-20% of all canine congenital cardiac anomalies. It is particularly prevalent in certain breeds, including the English Bulldog, Boxer, Beagle, Miniature Schnauzer, Chihuahua, and Cocker Spaniel. In the English Bulldog, the prevalence is notably high, with some studies reporting up to 30% of the breed affected. There is no strong sex predilection, though some reports suggest a slight male predominance. In cats, PS is rare, representing less than 5% of feline congenital heart defects, with no specific breed predisposition. The condition is typically diagnosed in young animals, often during routine physical examination or workup for a heart murmur, but mild cases may remain undetected until adulthood. Geographic variation is not significant, but breed popularity influences regional prevalence.

The fundamental pathophysiologic consequence of pulmonary stenosis is increased right ventricular afterload due to obstruction of blood flow from the right ventricle to the pulmonary artery. This pressure overload triggers concentric hypertrophy of the right ventricular myocardium, which initially compensates by maintaining cardiac output. However, as the obstruction worsens or hypertrophy progresses, right ventricular compliance decreases, leading to elevated diastolic pressures and increased right atrial pressure. The hypertrophied right ventricle may also become ischemic due to increased myocardial oxygen demand and reduced coronary perfusion, particularly in the subendocardial region. Over time, this can result in right-sided congestive heart failure, characterized by ascites, hepatomegaly, and peripheral edema. In severe cases, the obstruction can cause syncope or sudden death, likely due to arrhythmias or inadequate cardiac output during exercise. Additionally, the turbulent flow across the stenotic valve can cause post-stenotic dilation of the main pulmonary artery, which may be visible on radiographs. In some animals, concurrent infundibular hypertrophy can create a dynamic component to the obstruction, worsening the gradient.

The primary predisposing factor for pulmonary stenosis is genetic predisposition, with certain breeds having a significantly higher risk. A family history of congenital heart disease increases the likelihood. Other factors that may influence the severity and clinical manifestation include the specific anatomical type of stenosis (valvular vs. subvalvular), the degree of valve dysplasia, and the presence of concurrent congenital defects. Age at diagnosis is also a factor, as severe stenosis often presents in young animals, while mild stenosis may be an incidental finding in older pets. There are no known dietary, environmental, or management factors that predispose to the development of PS. However, obesity and poor physical conditioning can exacerbate clinical signs in affected animals.

Clinical signs of pulmonary stenosis vary widely depending on the severity of the obstruction. In mild cases, animals may be asymptomatic, and the condition is often detected as an incidental finding of a heart murmur. In moderate to severe cases, clinical signs may include exercise intolerance, lethargy, syncope, and dyspnea. As right-sided congestive heart failure develops, signs such as abdominal distension (ascites), peripheral edema, and jugular venous distension may appear. On physical examination, a systolic ejection murmur is typically heard over the left heart base, with radiation to the thoracic inlet. The murmur intensity may be grade III/VI to VI/VI, and a palpable precordial thrill may be present in severe cases. In some animals, a split S2 heart sound or a right-sided S4 gallop may be auscultated. Cyanosis is uncommon unless there is a right-to-left shunt through a patent foramen ovale or a concurrent ventricular septal defect. In severe cases, signs of right heart failure, such as hepatomegaly and ascites, are evident.

Differential diagnoses for pulmonary stenosis include other congenital heart defects that cause a systolic murmur and right heart enlargement. These include: 1. **Ventricular Septal Defect (VSD)**: A VSD typically produces a harsh holosystolic murmur at the right sternal border, and echocardiography reveals a defect in the interventricular septum with left-to-right shunting. 2. **Tetralogy of Fallot**: This complex defect includes PS, VSD, overriding aorta, and right ventricular hypertrophy. Cyanosis is often present, and echocardiography demonstrates all four features. 3. **Atrial Septal Defect (ASD)**: An ASD may cause a soft systolic murmur and right heart enlargement, but the murmur is usually not as loud as PS, and echocardiography shows an interatrial communication. 4. **Tricuspid Valve Dysplasia**: This condition causes right atrial enlargement and a systolic murmur of tricuspid regurgitation, but the murmur is typically heard at the right apex, and echocardiography reveals abnormal tricuspid valve morphology. 5. **Pulmonic Regurgitation**: This is usually a diastolic murmur, but if severe, it can cause right ventricular volume overload. Echocardiography shows pulmonary valve insufficiency. 6. **Infective Endocarditis**: Although rare, vegetative lesions on the pulmonary valve can cause obstruction and murmur. Blood cultures and echocardiography can differentiate. 7. **Heartworm Disease**: In endemic areas, heartworm infection can cause pulmonary hypertension and right heart failure, but the murmur is usually not a typical ejection murmur, and antigen testing is positive. 8. **Physiologic Murmur**: Innocent murmurs are common in young animals and can be mistaken for PS. Echocardiography is necessary to rule out structural disease.

The diagnostic approach to pulmonary stenosis begins with a thorough history and physical examination. If a systolic ejection murmur is detected over the left heart base, the following steps are recommended: 1. **Thoracic Radiography**: Assess for right ventricular enlargement (increased sternal contact on lateral view), main pulmonary artery dilation (bulge at the 1-2 o'clock position on dorsoventral view), and decreased pulmonary vascularity in severe cases. 2. **Electrocardiography (ECG)**: May show right axis deviation, deep S waves in leads I, II, and III, and P pulmonale (tall P waves) in cases of right atrial enlargement. 3. **Echocardiography**: This is the gold standard for diagnosis. Two-dimensional imaging reveals the anatomical type of stenosis (valvular, subvalvular, supravalvular), leaflet morphology, and right ventricular hypertrophy. Doppler echocardiography measures the peak systolic pressure gradient across the pulmonary valve using the modified Bernoulli equation (pressure gradient = 4 × velocity²). This gradient determines severity and guides treatment decisions. 4. **Advanced Imaging**: In complex cases, cardiac CT or MRI may be used to further delineate anatomy, especially for planning interventional procedures. 5. **Cardiac Catheterization**: This is rarely needed for diagnosis but may be performed during balloon valvuloplasty to measure pressures directly and assess the gradient. 6. **Additional Tests**: Blood work, including CBC, biochemistry, and NT-proBNP, may be performed to assess overall health and the presence of heart failure.

In uncomplicated pulmonary stenosis, routine laboratory findings are typically unremarkable. However, in cases of right-sided congestive heart failure, there may be elevations in liver enzymes (ALT, AST, ALP) due to hepatic congestion, and increased bilirubin. Serum albumin may be decreased in severe ascites due to loss into the peritoneal fluid. NT-proBNP (N-terminal pro-brain natriuretic peptide) may be elevated in animals with myocardial stretch or heart failure, and can be used as a biomarker to support the diagnosis of cardiac disease. Troponin I may be elevated if there is myocardial ischemia or damage. Arterial blood gas analysis is usually normal unless there is a right-to-left shunt causing hypoxemia. In animals with concurrent disease, such as heartworm infection, additional tests like antigen testing may be indicated.

**Radiography**: On thoracic radiographs, findings include right ventricular enlargement, characterized by increased sternal contact on the lateral view and a reversed D-shaped cardiac silhouette on the dorsoventral view. The main pulmonary artery may be dilated, appearing as a bulge at the 1-2 o'clock position on the dorsoventral view. Pulmonary vascularity may be normal or decreased in severe cases. In right heart failure, there may be hepatomegaly, ascites (loss of abdominal detail), and pleural effusion. **Echocardiography**: This is the primary imaging modality. Two-dimensional echocardiography shows the thickened, domed pulmonary valve leaflets in valvular stenosis, or a fibrous band in subvalvular stenosis. Right ventricular concentric hypertrophy is evident. Doppler echocardiography (continuous-wave) measures the peak systolic velocity across the pulmonary valve, from which the pressure gradient is calculated. Color-flow Doppler may show turbulent flow. In severe cases, right atrial enlargement and tricuspid regurgitation may be present. **Advanced Imaging**: Cardiac CT or MRI can provide detailed anatomical information, especially for complex lesions or for planning balloon valvuloplasty. These modalities are particularly useful in cases where echocardiography is inconclusive.

Cytology and histopathology are not typically used in the diagnosis of pulmonary stenosis. However, if a lung biopsy is performed for other reasons, histopathology may show changes consistent with pulmonary hypertension, such as medial hypertrophy of pulmonary arterioles. In cases of right heart failure, liver biopsy may show centrilobular congestion and fibrosis. These findings are nonspecific and not diagnostic for PS.

Treatment of pulmonary stenosis depends on the severity of the obstruction and the presence of clinical signs. For asymptomatic animals with mild stenosis (gradient <50 mmHg), no treatment is required, but regular monitoring is recommended. For animals with moderate to severe stenosis (gradient >50 mmHg) or clinical signs, intervention is indicated. **Medical Therapy**: In animals with right heart failure, diuretics (e.g., furosemide 1-2 mg/kg PO q8-12h) and an ACE inhibitor (e.g., enalapril 0.5 mg/kg PO q12h) may be used to manage fluid retention. Beta-blockers (e.g., atenolol 0.25-1 mg/kg PO q12h) may be used to reduce myocardial oxygen demand and control arrhythmias, but they should be used with caution as they can worsen the obstruction by reducing contractility. **Interventional Therapy**: Balloon valvuloplasty is the treatment of choice for valvular pulmonary stenosis. This procedure is performed under general anesthesia, and a balloon catheter is advanced across the pulmonary valve and inflated to dilate the stenotic orifice. The success rate is high, with a significant reduction in the pressure gradient. Complications include pulmonary artery rupture, arrhythmias, and residual stenosis. **Surgical Therapy**: Surgical correction (open valvotomy or patch grafting) is reserved for cases where balloon valvuloplasty is not feasible or has failed, such as in severe subvalvular stenosis or dysplastic valves. Surgery carries higher morbidity and mortality. **Supportive Care**: Exercise restriction is recommended for animals with moderate to severe stenosis. In cases of syncope, immediate veterinary attention is required.

The prognosis for pulmonary stenosis varies with severity. Animals with mild stenosis have a normal life expectancy and are often asymptomatic. Those with moderate stenosis may have a good quality of life with appropriate management, but may be at risk for progression. Severe stenosis carries a guarded prognosis, especially if clinical signs are present. Without intervention, severe PS can lead to right heart failure and sudden death. Balloon valvuloplasty significantly improves the prognosis, with many animals becoming asymptomatic and having a good long-term outcome. The presence of concurrent congenital defects or arrhythmias worsens the prognosis.

Animals with pulmonary stenosis should be monitored regularly. For mild cases, re-evaluation every 6-12 months is recommended. For moderate to severe cases, more frequent monitoring (every 3-6 months) is advised. Follow-up should include physical examination, echocardiography to assess the pressure gradient and right heart size, and thoracic radiography if heart failure is suspected. After balloon valvuloplasty, re-evaluation at 1, 3, 6, and 12 months post-procedure is recommended, then annually. Serial NT-proBNP measurements may be useful to monitor cardiac status. Owners should be educated on signs of heart failure and syncope, and advised to seek immediate veterinary care if these occur.

**Pearls**: - Always auscultate the left heart base carefully for a systolic ejection murmur; a palpable thrill indicates severe stenosis. - Echocardiography is essential for accurate diagnosis and grading; Doppler gradient is the key measurement. - Balloon valvuloplasty is highly effective for valvular stenosis and can be curative in many cases. - In asymptomatic animals with mild stenosis, no treatment is needed, but regular monitoring is crucial. **Pitfalls**: - Do not rely solely on radiography; it may be normal in mild cases. - Avoid using beta-blockers in animals with severe stenosis as they can reduce cardiac output and worsen clinical signs. - Do not delay intervention in animals with moderate to severe stenosis, as they are at risk for sudden death. - Be cautious with anesthesia in these animals; use a cardiopulmonary sparing protocol.

**Furosemide**: 1-2 mg/kg PO, IV, IM, SC q8-12h. Use with caution in renal impairment. Monitor electrolytes and hydration. **Enalapril**: 0.5 mg/kg PO q12h. Adjust dose in renal impairment. Monitor renal function and potassium. **Atenolol**: 0.25-1 mg/kg PO q12h. Start at low dose and titrate. Avoid in animals with bradycardia or heart block. **Pimobendan**: 0.25-0.3 mg/kg PO q12h. May be used in cases of right heart failure to improve contractility, but evidence is limited. **Spironolactone**: 1-2 mg/kg PO q12h. May be used as an adjunct diuretic in heart failure. **Antibiotics**: Not indicated unless there is concurrent infection. **Analgesics**: Not typically required unless post-operative. All dosages are based on Plumb's Veterinary Drug Handbook and should be adjusted based on individual patient response and organ function.

The management of pulmonary stenosis has been informed by several key studies. A landmark study by Buchanan (1992) described the breed predisposition and natural history of PS in dogs. The ACVIM consensus statement on congenital heart disease (2015) provides guidelines for diagnosis and treatment, recommending balloon valvuloplasty for moderate to severe stenosis. A study by Estrada et al. (2006) reported successful outcomes with balloon valvuloplasty in dogs, with a significant reduction in pressure gradient and improvement in clinical signs. Another study by Bussadori et al. (2001) compared surgical and interventional outcomes, showing that balloon valvuloplasty is associated with lower morbidity and mortality. In cats, PS is rare, and treatment recommendations are extrapolated from canine studies. Overall, the evidence supports early intervention for severe PS to improve prognosis and quality of life.